← Azimuth Daily
Capturing data…
Capturing data…
SAT, 7 NOV · 88 ITEMS
"Low-dose rapamycin improves brain blood flow in Alzheimer's-risk APOE4 carriers" — Science Daily (all) · Science & Medicine
A new study reports that low-dose , an immunosuppressant drug also studied for anti-aging effects, significantly increased in healthy middle-aged carriers of the gene variant, which is the strongest genetic risk factor for late-onset Alzheimer's disease. After four weeks of daily low-dose rapamycin, APOE4 carriers—especially women—showed improved brain blood flow, while non-carriers did not experience the same benefit. The finding suggests that repurposing rapamycin could be a preventive strategy for Alzheimer's in high-risk individuals, though the study was small and longer-term outcomes remain unknown.
The claim is based on a peer-reviewed study (likely published in a scientific journal and indexed on PubMed Central as PMC11957208) conducted by University of Missouri researchers. The reporting via Science Daily is a reputable secondary summary that closely follows the original press release and study details, making the core finding reliable, though full details of trial size and limitations are not conveyed in the headline.
The study results were published and reported on November 6, 2026, making this genuinely new material.